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Abstract:  The  conventional  view  is  that  alcohol  metabolism  is  carried  out  by  ADH1  
(Class  I)  in  the  liver.  However,  it  has  been  suggested  that  another  pathway  plays  an 
important role in alcohol metabolism, especially when the level of blood ethanol is high or 
when drinking is chronic. Over the past three decades, vigorous attempts to identify the 
enzyme responsible for the non-ADH1 pathway have focused on the microsomal ethanol 
oxidizing system (MEOS) and catalase, but have failed to clarify their roles in systemic 
alcohol metabolism. Recently, using ADH3-null mutant mice, we demonstrated that ADH3 
(Class III), which has a high Km and is a ubiquitous enzyme of ancient origin, contributes 
to systemic alcohol metabolism in a dose-dependent manner, thereby diminishing acute 
alcohol intoxication. Although the activity of ADH3 toward ethanol is usually low in vitro 
due to its very high Km, the catalytic efficiency (kcat/Km) is markedly enhanced when the 
solution  hydrophobicity  of  the  reaction  medium  increases.  Activation  of  ADH3  by 
increasing hydrophobicity should also occur in liver cells; a cytoplasmic solution of mouse 
liver cells was shown to be much more hydrophobic than a buffer solution when using Nile 
red as a hydrophobicity probe. When various doses of ethanol are administered to mice, 
liver ADH3 activity is dynamically regulated through induction or kinetic activation, while 
ADH1 activity is markedly lower at high doses (3–5 g/kg). These data suggest that ADH3 
plays  a  dynamic  role  in  alcohol  metabolism,  either  collaborating  with  ADH1  or 
compensating for the reduced role of ADH1. A complex two-ADH model that ascribes 
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total liver ADH activity to both ADH1 and ADH3 explains the dose-dependent changes in 
the pharmacokinetic parameters (, CLT, AUC) of blood ethanol very well, suggesting that 
alcohol metabolism in mice is primarily governed by these two ADHs. In patients with 
alcoholic liver disease, liver ADH3 activity increases, while ADH1 activity decreases, as 
alcohol intake increases. Furthermore, ADH3 is induced in damaged cells that have greater 
hydrophobicity, whereas ADH1 activity is lower when there is severe liver disease. These 
data  suggest  that  chronic  binge  drinking  and  the  resulting  liver  disease  shifts  the  key 
enzyme in alcohol metabolism from low-Km ADH1 to high-Km ADH3, thereby reducing 
the rate of alcohol metabolism. The interdependent increase in the ADH3/ADH1 activity 
ratio and AUC may be a factor in the development of alcoholic liver disease. However, the 
adaptive increase in ADH3 sustains alcohol metabolism, even in patients with alcoholic 
liver cirrhosis, which makes it possible for them to drink themselves to death. Thus, the 
regulation of ADH3 activity may be important in preventing alcoholism development. 
Keywords: ADH1; ADH3; contribution to alcohol metabolism; enzyme regulation; role 
shift; alcoholic liver disease 
 
 
1. Introduction 
The pharmacologic and potentially pathologic effects of alcohol depend on the concentrations of 
ethanol and its metabolites in the body, and on the duration of exposure to these substances. When the 
body ingests ethanol, there is an initial equilibration phase, after which both the concentrations and 
duration of these substances in the body are primarily governed by the rate of ethanol metabolism. So, 
the elucidation of the mechanism of alcohol metabolism is essential to the understanding and control of 
the action of alcohol in the body. 
Alcohol  dehydrogenase  (ADH)  1  (Class  I  ADH)  is  the  key  enzyme  in  alcohol  metabolism  
in vivo [1]. However, it has been demonstrated that systemic alcohol metabolism involves another 
pathway  independent  of  ADH1  [2,3].  This  was  originally  called  the  non-ADH1  pathway,  and  is 
thought  to  play  a  major  role  in  alcohol  metabolism  for  acute  intoxication  and  for  chronic  
drinkers [2-7]. Thus, the identification of the enzyme in this pathway has long been the subject of 
heated scientific debate, with  the main candidates  being the microsomal  ethanol oxidizing system 
(MEOS) and catalase [2-12]. However, the contributions of these two enzymes to systemic alcohol 
metabolism have still not been clarified. 
In 1978, we found a new type of ADH in mouse liver [13,14], which was later classified as Class 
III ADH (ADH3) [14,15], and have continued to investigate its enzymatic characteristics and its role in 
alcohol  metabolism  [16-24].  Recently,  we  used  ADH3-null  mutant  mice  to  demonstrate  that  the 
contribution of ADH3 to alcohol metabolism in vivo increases dose-dependently [25]. 
In this review, we argue for a new view of ADH3 in alcohol metabolism and in the development of 
alcoholism, and compare it with ADH1, which has the starring role in the field of alcohol medicine. 
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2. Historical Debate on the Identification of Enzyme(s) in the So-Called ‘Non-ADH’ Pathway* of 
Alcohol Metabolism 
Animal experiments using pyrazoles, which are specific inhibitors of ADH, have left no doubt that 
ADH1 is the main enzyme responsible for alcohol metabolism in the body [1]. However, alcohol 
continues to be metabolized to some extent even after the administration of pyrazoles; this is called the 
non-ADH pathway [2,3]. This pyrazole-insensitive pathway has a greater metabolic role when the 
level  of  blood  alcohol  is  high  or  when  the  intake  of  alcohol  is  chronic  [2-7].  Recently,  we  used  
ADH1-null mice to show that ADH1 accounts for about 70% of systemic alcohol metabolism [25,26], 
which means that the non-ADH1 pathway accounts for the remaining 30%. Regarding the identity of 
the  main  enzyme  responsible  for  this  pathway,  a  heated  scientific  debate  has  continued  for  three 
decades over whether it is catalase [10-12] or MEOS, which is mainly composed of CYP2E1 [2-9]. 
Indeed,  both  enzymes  seem  to  be  responsible  for  the  non-ADH1  pathway,  because  both  exhibit 
ethanol-oxidizing activity with a Km for ethanol (around 10 mM [7,10]) that is higher than that for 
ADH1, and both  are insensitive to  pyrazoles in vitro  [2-6]. Furthermore, the induction  of MEOS 
activity  due  to  chronic  alcohol  consumption  seems  to  explain  the  accelerated  rate  of  alcohol 
metabolism observed in chronic drinkers [3,5-7]. However, it has recently been demonstrated that 
there  is  no  difference  in  the  elimination  rate  for  blood  ethanol  between  CYP2E1-null  mice  and  
wild-type mice, even after the chronic administration of ethanol [27]. The role of catalase in systemic 
alcohol  metabolism  has  not  been  clarified  in  vivo  either,  even  though  mice  genetically  lack  this 
enzyme [28]. Since there is no in-vivo evidence for either MEOS or catalase, the debate still has not 
reached a conclusion. Furthermore, the first-order kinetics of the elimination of blood alcohol has been 
observed at very high concentrations [29-31], which cannot be explained by the Km of either MEOS [7] 
or  catalase  [10].  These  data  suggest  the  involvement  of  a  very  high-Km  enzyme  in  the  
non-ADH pathway. 
Many investigators have reported that the total ADH activity of liver correlates with the rate of 
systemic alcohol metabolism [1]. Mammalian livers are known to contain two ADH isozymes other 
than ADH1, namely, ADH2 (Class II) and ADH3 (Class III), both of which have a higher Km for 
ethanol than ADH1 [32]. These data suggest a possible role for these high-Km ADHs in the non-ADH1 
pathway of alcohol metabolism. 
3. Discovery of ADH3 (Class III ADH) 
In 1981, X. Pares and B. L. Vallee reported a new form of human liver ADH with unique kinetic 
characteristics [33] and classified it as Class III ADH (ADH3) because it was the third isozyme of 
mammalian ADH to be discovered [15]. However, two years earlier in 1979, at a meeting on alcohol 
medicine in Japan [13], we reported that we had found a new type of ADH with an acidic isoelectric 
point in mouse liver that had a very high Km for ethanol and was insensitive to pyrozoles. The new 
mouse ADH corresponded to an electrophoretic ADH band previously designated as ADHB2 on a  
gel [14,34] and was later also classified as Class III ADH (ADH3) [14,33]. Around that time, many 
investigators considered ADH3 to have a negligible role in alcohol metabolism because it exhibits only 
very low activity towards ethanol due to its very high Km when measured in vitro by the standard ADH Int. J. Environ. Res. Public Health 2010, 7                 
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assay using 15 mM ethanol as a substrate [33]. However, when the ADH3 fraction was separated from 
other ADH isozymes of mouse liver by CM-chromatography, it was found to account for about 13% of 
total  liver  ADH  activity;  ADH1  accounts  for  more  than  62%,  and  ADH2  accounts  for  only  2%. 
Moreover, as the concentration of substrate ethanol increased, the percentage of the ADH3 fraction 
increased while that of the ADH1 fraction decreased. So, we speculated that ADH3 plays a significant 
role in alcohol metabolism [24]. 
4. Activation of ADH3 by Solution Hydrophobicity and Dynamic Metabolism of Alcohol 
Mouse ADH1 shows the largest activity towards ethanol around 10 mM (Km ≒ 1 mM), and the 
activity decreases in a dose-dependent manner as the concentration becomes higher. In contrast, ADH3 
shows a low activity towards ethanol at several tens of millimoles, but the activity increases linearly up 
to the molar level (Km < 1 M) [15,16]. However, we have sometimes observed that ADH3 is activated 
during  the  purification  process  when  measured  by  the  standard  ADH  assay.  By  investigating  the 
regulation of its activity under various conditions, we found that solution hydrophobicity markedly 
activated ADH3 and increased its catalytic efficiency (kcat/Km) for ethanol [20,25]. Tert-butanol (C4), 
which strongly induces solution hydrophobicity in a medium due to its strong hydrophobic hydration 
and its high miscibility, increases the kcat/Km of ADH3 almost ten-fold, lowering its Km for ethanol. 
The Km decreases below 100 mM by solution hydrophobicity induced with tert-butanol above 1.8 M 
(unpublished data). Since we observed no significant changes in the secondary, tertiary, or quaternary 
structures  of  mouse  ADH3  in  hydrophobic  solution,  we  concluded  that  solution  hydrophobicity 
induces a slight structural change in the substrate-binding pocket of ADH3 [25]. Indeed, the reason 
why ADH3 has a low activity for ethanol is that the volume of its substrate-binding pocket is larger 
than that of ADH1 due to the substitution of smaller, more hydrophilic amino acid residues [35]. The 
hydrophilic amino acids constituting the pocket of ADH3 collapse in a hydrophobic medium, thus, 
reducing the size of the pocket. This structural change may raise its affinity for a small molecule like 
ethanol, thereby increasing its ability to oxidize ethanol. Thus, solution hydrophobicity lowers the Km 
of ADH3 and increases it activity with respect to ethanol. The increase in activity in a hydrophobic 
solution is specific to ADH3; all other ADH isozymes show a decrease in activity in this type of 
medium [20]. 
In  contrast  to  water  molecules  in  vitro,  intracellular  ones  are  dynamically  restrained  by  their 
hydrophobic interaction with various macromolecules and intracellular membranes with an extensive 
reticulum [36]. When Nile red, a fluorescent probe for hydrophobicity, is added to the cytoplasm of 
mouse liver, its spectrum is red-shifted from the spectrum obtained when it is added to a lipid droplet 
or a membrane of the liver, reflecting the hydrophobicity of a cytoplasmic solution [25]. Thus, also  
in vivo, ADH3 should be activated and ADH1 activity should be depressed by solution hydrophobicity 
in  the  liver  cells.  It  is  reasonable  to  conclude  that  both  ADHs  have  dynamic  roles  in  alcohol 
metabolism, with their activities being inversely regulated by changes in the solution hydrophobicity 
of liver cells. 
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5. Role of ADH3 in Systemic Alcohol Metabolism and in the Action of Alcohol in the Body— 
in vivo Evidence from ADH-knockout Mice 
In order to clarify the roles of ADH1 and ADH3 in systemic alcohol metabolism and in the action 
of alcohol in the body at various ethanol doses, we investigated the rate of alcohol metabolism (EDR: 
mg/kg/h) in wild-type mice (Wild), ADH1-null mutant mice (Adh1-/-) and ADH3-null mutant mice 
(Adh3-/-) by the administration of ethanol at doses ranging from 1.0 to 4.5 g/kg [25]. Compared to the 
EDR of Wild, that of Adh3-/- decreased markedly as ethanol dose increased and was about 66% of that 
of Wild at a dose of 4.5 g/kg. These data demonstrate that ADH3 contributes to systemic alcohol 
metabolism in a dose-dependent manner in vivo, with the contribution being over 30% at large doses. 
These  data  also  indicate  that  the  contribution  of  ADH1  to  alcohol  metabolism  decreases  
dose-dependently  because  ADH1  is  the  only  major  alcohol-metabolizing  enzyme  in  Adh3-/-.  In 
addition, the EDR of Adh1-/- was 21-33% that of Wild, which indicates that the contribution of ADH1 
to systemic alcohol metabolism is more than 60% but less than 80%, and decreases dose-dependently. 
Thus,  we  conclude  that  the  contribution  of  ADH3  to  alcohol  metabolism  increases  as  the  dose 
increases, thereby compensating for the reduced role of ADH1. Moreover, when the ethanol dose is 
large, ADH1 and ADH3 together account for almost all the alcohol metabolism of Wild. 
The duration of the loss of the righting reflex (LORR) in mice, which is the length of time that a 
mouse sleeps after the administration of enough ethanol to produce acute intoxication, was longer in 
the order Adh1-/-, Adh3-/-, and Wild. The frequency of mortality at large doses also increased in the 
order Adh1-/-, Adh3-/-, and Wild. These data demonstrate that, in vivo, ADH3 diminishes acute alcohol 
intoxication together with ADH1, by participating in alcohol metabolism in a dose-dependent manner. 
6. The Role of ADH3 in First-Pass Metabolism 
After drinking alcohol, it is partially metabolized in the digestive organs including the liver, before 
entering the systemic circulation of blood. The concentration of alcohol reaches a molar level in these 
organs. It is possible for ADH3 to play an important role in this first-pass metabolism (FPM) because 
it has a very high Km for ethanol and is present not only in the liver but also in the stomach and small 
intestine. Indeed, the ADH-3 activity in the stomach and the FPM are smaller for women than for  
men  [37].  Furthermore,  we  found  that,  in  mouse  liver,  ADH3  highly  distributes  in  sinusoidal 
endothelial cells, in contrast to ADH1, which is present only in parenchymal cells [19]. So, it seems 
that,  when  a  high  concentration  of  alcohol  is  carried  from  a  portal  vein  to  the  liver,  it  is  first 
metabolized by high-Km ADH3 in sinusoidal endothelial cells; and then, after ADH3 has lowered the 
concentration, the remained ethanol is metabolized by low-Km ADH1 in parenchymal cells. Thus, the 
FPM  of  alcohol  in  the  liver  may  involve  a  two-step  process  employing  both  ADHs,  which  have 
different Kms for ethanol and different tissue distributions. ADH3 may play the role of a gatekeeper 
that protects the parenchymal cells from the high toxicity of high concentrations of alcohol. 
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7. Dynamic Contribution of ADH3 to Alcohol Metabolism through Regulation of Activity by 
Ethanol Administration 
When a small dose (1 g/kg) of ethanol is administered to mice, the blood alcohol concentration 
(BAC) reaches around 20 mM, at which ADH1 shows the maximum activity. This level of BAC is 
also observed in people who become slightly drunk after imbibing about two 633-mL bottles of beer. 
A  medium  dose  (3  g/kg)  causes  mice  to  lose  the  righting  reflex  for  several  minutes  just  after 
administration,  and  the  BAC  is  around  60  mM.  A  large  dose  (5  g/kg)  produces  acute  alcohol 
intoxication with a BAC of over 100 mM, and the righting reflex is lost for several hours [24,25]. 
To investigate how the activities of ADH1 and 3 change during alcohol metabolism and what their 
relative contributions are, we periodically measured total liver ADH activity and the content of the two 
ADHs after various doses of ethanol were administered to mice [24]. When measured by the standard 
ADH assay using 15 mM ethanol as a substrate, the total liver ADH activity involved not only ADH1 
but also ADH3, from the data that the total activity correlates more strongly with the sum of two ADH 
contents than with just the ADH1 content. When the ethanol dose was small, the contents of both 
ADHs in the liver increased, resulting in about a 41% increase in total liver ADH. Thus, both ADHs 
are acutely induced in the liver and actively participate in alcohol metabolism at moderate drinking. 
The acute induction of ADH isozymes, which are due to increases in mRNA [38], are known to occur 
in yeast [39] and plant [40] cells in hypoxic conditions. These data suggest that the acute induction of 
liver ADHs observed in mouse by a small dose of ethanol is also due to hypoxic conditions of the liver 
cell, where NADH/NAD ratio is increased by ethanol metabolism [41]. ADH3 may be related to brain 
disorders due to hypoxia, because it distributes in the brain in areas that are vulnerable to ischemia or 
hypoxic cerebropathy [23] as the sole ADH isozyme in the brain [42]. When the ethanol dose was 
medium  [24],  the  liver  ADH1  content  decreased  from  the  early  stages  to  the  end  of  alcohol 
metabolism. On the other hand, the liver ADH3 content increased in the early stages, but decreased in 
later stages, which is similar to the time-wise change found in the total ADH activity of the liver. For a 
large dose [24], the content of both ADHs in the liver markedly decreased, starting just after ethanol 
administration,  which  resulted  in  a  marked  decrease  in  total  ADH  activity.  However,  the  ADH3 
content recovered and increased in the later stages of alcohol metabolism, although that of ADH 1 kept 
decreasing to the end. Thus, at intoxicating doses of ethanol, ADH3 makes a positive contribution to 
alcohol  metabolism,  as  shown  by  the  time-wise  change  in  its  content  in  the  liver  during  alcohol 
metabolism, whereas the contribution of ADH 1 decreases because its content in the liver decreases. 
Another point is that the ADH3 activity of liver extract can be measured by using hexenol as a 
substrate and 4-methylpyrazole to inhibit ADH1 [43]. Even though the ADH3 content exhibited a 
time-dependent change at intoxicating doses of ethanol (3, 5 g/kg), the ADH3 activity assayed by this 
method remained high during alcohol metabolism, as observed for the small dose [44]. Furthermore, 
the catalytic  efficiency  (Vmax/Km) of the ADH activity of liver  extract  for ethanol increased dose-
dependently [45]. These data suggest that at intoxicating doses of ethanol, ADH3 activity remains high 
by regulation of both enzyme composition and enzyme kinetics to compensate for the reduced role of 
ADH1  in  alcohol  metabolism.  Thus,  both  ADH1  and  ADH3  contribute  to  alcohol  metabolism, 
dynamically changing the enzyme composition and kinetics. Int. J. Environ. Res. Public Health 2010, 7                 
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8. A Complex Two-ADH Model to Explain Pharmacokinetics of Blood Alcohol 
In mice [24,45], the alcohol clearance (CLT: dose/AUC) decreased in a dose-dependent manner up 
to a dose of 5 g/kg, and exhibited a significant correlation with average total liver ADH activity during 
alcohol metabolism. The elimination rate for blood alcohol (β) reached a maximum at an ethanol dose 
of 2 g/kg, which corresponds to the Vmax of Michaelis-Menten (M-M) elimination kinetics. However, 
above a dose of 2 g/kg,  decreased as the dose increased, as CLT decreased. The decrease in β above a 
medium  dose  has  also  been  observed  in  rats  [46,47].  On  the  other  hand,  the  normalized  AUC 
(AUC/dose), which exhibited a nonlinear, dose-dependent increase, had an inverse correlation with β. 
To explain how alcohol-metabolizing enzymes regulate the pharmacokinetics of blood alcohol in 
mice, we have devised a complex two-ADH model in which the total liver ADH activity involves not 
only ADH1 but also ADH3 [24,45]. According to the model, liver ADH activity is a function of four 
variables:  ADH1 activity,  ADH1  content, ADH3 activity, and ADH-3  content. Since liver ADH3 
activity  is  determined  not  only  by  the  change  in  content  but  also  by  the  change  in  kinetics,  as 
mentioned in the previous section, we make the following definitions: 
liver ADH3 activity = total liver ADH activity – liver ADH1 activity, and 
liver ADH1 activity = liver ADH1 content  Vmax/mg for purified ADH1. 
When the activities of both ADHs are normalized by the ratio of the liver ADH activity of mice to 
which  ethanol  was  administered  mice  to  that  of  control  mice,  the  ADH3  activity  increased  
dose-dependently,  whereas  that  of  ADH1  decreased.  The  ADH3/ADH1  activity  ratio  correlates 
directly with AUC/dose, and inversely with CLT and β. So, the dose-dependent increase in AUC is 
explained by the dose-dependent increase in the ADH3/ADH1 activity ratio, which causes the body 
clearance (CLT) and elimination rate (β) of alcohol metabolism to decrease. 
Thus, the complex two-ADH model explains the changes in various pharmacokinetic parameters of 
blood alcohol in mice, suggesting that, as the ethanol dose increases, the elimination kinetics of blood 
alcohol shift from M-M kinetics dominated by ADH1 to first-order kinetics dominated by ADH3 [45]. 
The first-order elimination kinetics of blood ethanol has been observed in humans at blood ethanol 
levels above 100 mM [29,30]. As the ethanol dose increases, the shift in enzyme from a low-Km ADH 
to a high-Km ADH causes a nonlinear increase in AUC due to the lowered metabolic rate while the 
ability of alcohol to be metabolized is maintained. These metabolic changes may qualitatively enhance 
the toxicity of alcohol. 
9. Regulation of ADH3 Activity in Chronic Ethanol Feeding and its Role in Alcohol Metabolism 
Animal experiments on chronic ethanol feeding have usually been performed on rats using a liquid 
diet (Lieber diet) containing 5% ethanol, which corresponds to 36% of the total caloric intake. In these 
experiments, liver MEOS shows increased activity, whereas liver ADH shows reduced or unchanged 
activity after four weeks of feeding, which accelerates alcohol metabolism and causes a severe case of 
fatty liver [7]. Based on these data, it has been thought that the acceleration of alcohol metabolism in 
chronic drinking is due to the induction of MEOS. However, it has recently been shown that there is no 
difference in the elimination rate for blood ethanol between CYP2E1 (a major component of MEOS)-Int. J. Environ. Res. Public Health 2010, 7                 
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null  mice  and  wild-type  mice,  even  after  chronic  ethanol  feeding  [27].  These  data  show  that  the 
acceleration of alcohol metabolism caused by chronic ethanol feeing is not related to MEOS. 
We  investigated  the  effects  of  chronic  ethanol  feeding  on  liver  ADH  isozymes  under  milder 
conditions than usual, using mice with about twice the rate of alcohol metabolism as that of rats and a 
liquid diet containing 4% ethanol, which corresponds to 28% of the total caloric intake [48]. After one 
week of feeding, the rate of alcohol metabolism increased as the total liver ADH activity increased, 
which was due to an increase in the liver ADH1 content. This situation continued until the 24th week 
of feeding, when a moderate case of fatty liver was observed. So, it seems that ADH1 adaptively 
contributes to the acceleration of alcohol metabolism induced by chronic ethanol feeing until the liver 
becomes moderately fatty, but that the contribution decreases as liver disease progresses, as observed 
in rats with a severe case of fatty liver. 
On the other hand, the liver ADH3 content markedly increased with the acute administration of a 
large dose (4.5 g/kg) of ethanol to mice during chronic ethanol feeding, although the liver  ADH3 
content did not significantly change when chronic ethanol feeding was mild [48]. This phenomenon 
may be related to  acute alcoholic hepatitis or pancreatitis.  It has been suggested that only  ADH3 
metabolizes ethanol in pancreatic acinar cells, which have almost the same ability to metabolize high 
concentrations of alcohol (50 mM) as hepatocytes do [49]. This also suggests that ADH3 is related to 
alcoholic pancreatic disease. 
10. Induction of ADH3 Due to Cell Damage Accompanied by Increased Hydrophobicity 
ADH3 is strongly expressed in human atherosclerotic lesions of the coronary artery and in cultured 
rat smooth-muscle cells after lipofection, in both of which membrane damage and a hydrophobic state 
were  observed  [22].  These  data  suggest  that  ADH3  is  induced  by  cell  damage  accompanied  by 
increased hydrophobicity. So, the increase in liver ADH3 content observed in mice in the late stages of 
alcohol metabolism after the administration of a large dose of ethanol (Section 6) may be due to the 
cell damage and fatty change, which are observed in mouse liver late after a large dose of ethanol [50]. 
The marked increase in liver ADH3 content observed after the acute administration of a large dose of 
ethanol  to  chronic-ethanol-fed  mice  (Section  8)  might  have  the  same  cause.  Thus,  the  activity  of 
ADH3 in the cells seems to be dynamically regulated by various intracellular conditions, for example, 
at  the  kinetic  level,  by  solution  hydrophobicity  (Section  5),  and  at  the  enzyme  content  level,  by 
hypoxia (Section 6) or by cell damage accompanied by increased hydrophobicity. ADH3 tends to be 
expressed especially strongly in cells in a critical condition because it plays a fundamental role in cell 
functions as the evolutionary ancestor of ADH, in contrast to ADH1, which differentiated from ADH3. 
The chronic intake of a large amount of alcohol forces to enhance ADH3 activity, but suppress ADH1 
activity, through increased solution hydrophobicity and cell damage. Furthermore, ADH3 activity may 
be elevated throughout the body of alcoholics because it is ubiquitous. Thus, ADH 3 may play a 
greater role in the alcohol metabolism of alcoholics. 
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11. Role of ADH3 in Liver Disease and the Alcohol Metabolism of Alcoholics 
When hexenol is used as a substrate in an ADH assay, 4-methlypyrazole has no effect on ADH3 
activity, but it completely inhibits ADH1 activity [43]. So, we used hexenol and 4-methlypyrazole to 
measure the liver ADH1 and ADH3 activities of alcoholics with liver disease [18]. The total ADH and 
ADH1 activities of biopsied livers correlate directly with each other and inversely with the amount of 
alcohol intake per day. These activities are relatively high in normal livers and in livers with mild 
fibrosis, but are low in fatty livers and very low in livers with severe fibrosis and cirrhosis. Taking 
these results together with those for chronically-ethanol-fed mice (Section 8), we conclude that chronic 
drinking adaptively increases ADH1 activity to accelerate alcohol metabolism until the onset of mild 
liver disease. However, a further increase in alcohol intake reduces  ADH1 activity and its role in 
alcohol  metabolism  due  to  the  development  of  liver  disease.  On  the  other  hand,  ADH3  activity 
significantly  correlates  with  a  person’s  total  alcohol  intake,  which  strongly  correlates  with  the 
development of liver disease. Consequently, ADH3 activity inversely correlates with ADH1 activity in 
alcoholic patients. This relationship can be also explained by the idea that ADH 3 is induced by cell 
damage accompanied by increased hydrophobicity. In addition, capillarization of the liver due to liver 
cirrhosis  may  also  increase  the  amount  of  ADH3,  because  it  is  mainly  found  in  the  sinusoidal 
endothelial cells of the liver [19]. The highest incidence of liver cirrhosis is observed in patients with a 
high  ADH3/ADH1  activity  ratio  plus  low  total  liver  ADH  activity.  As  discussed  in  the  complex  
two-ADH model for mice, the key enzyme in alcohol metabolism may also shift from ADH1 to ADH3 
in alcoholic patients with severe liver disease. For these patients, liver disease may have developed 
through  a  nonlinear  increase  in  AUC  due  to  an  increase  in  the  ADH3/ADH1  activity  ratio  that 
accompanies the lower rate of alcohol metabolism. 
Cases are not rare in which alcoholics with liver cirrhosis visit a hospital after drinking a great deal 
of  alcohol  the  day  before.  How  can  they  drink  so  much  even  though  ADH1,  MEOS  [51],  and  
catalase [52], which are well-known alcohol-oxidizing enzymes, all have a low activity in their livers? 
It is difficult to explain the alcohol metabolism of such patients solely in terms of these enzymes. On 
the other hand, ADH3 is induced by cell damage that produces hydrophobicity [22] and positively 
correlates with lifetime total alcohol intake [18], which is strongly related to the development of liver 
disease. So, this ADH may maintain the ability of alcoholic patients to metabolize alcohol in spite of 
severe liver disease, thereby making it possible for them to drink a great deal. 
In summary, the development of alcoholism is adequately described by a complex two-ADH model. 
Chronic drinking accelerates alcohol metabolism by means of an adaptive increase in ADH1 activity 
(and also ADH3 activity under some conditions) during the non-pathological stage. Induced alcohol 
resistance increases the amount of alcohol that can be imbibed, and leads to heavy drinking. The 
increased AUC from heavy drinking elevates the cellular toxicity and central-nervous-system toxicity 
of  alcohol.  Cell  damage  accompanied  by  hydrophobicity  reduces  the  rate  of  alcohol  metabolism 
through an increase in the ADH3/ADH1 activity ratio, which in turn produces a further nonlinear 
increase in AUC. The vicious cycle of an interdependent increase in the ADH3/ADH1 activity ratio 
and AUC in alcohol dependence may further develop liver disease and induce cirrhosis of the liver. 
However, this adaptation of ADH3 to alcohol metabolism may mean suicide to alcoholics, because it 
makes it possible for them to keep on drinking by maintaining the ability to metabolize alcohol even Int. J. Environ. Res. Public Health 2010, 7                 
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when there is severe liver disease, which could be fatal. This seems to be an adaptive discrepancy in 
human physiology. From another standpoint, however, the regulation of ADH3 activity seems to be a 
key to resolving the problem of alcoholism. 
12. Other ADH Isozymes in Alcohol Metabolism 
ADH2 (Class II), which shows limited distribution to the liver [53], seems to be insignificant in 
alcohol metabolism of rodents, because mouse ADH2 is responsible for only a small part of the total 
ADH activity in the liver (Section 3). On the other hand, human ADH2 is known to be highly active 
towards  ethanol  [54],  and  is  suggested  to  contribute  to  alcohol  metabolism  [55,56].  However,  its 
contribution  possibility  to  systemic  alcohol  metabolism  may  become  lower  in  habitual  drinking, 
because ADH2 activity has been demonstrated to be decreased in baboon liver by moderate drinking 
and to be almost abolished by heavy drinking [57]. 
ADH4 (Class IV) also shows restricted distribution to gastric mucosa, exhibiting different kinetics 
for ethanol between human (Km = ~37 mM) and rodents (Km = ~2.4 M) [58]. The catalytic efficiency 
is about 40-times higher in human than in rodent. However, the tissue content of human ADH4 in 
gastric mucosa is approximately 10 μg/g tissue [58], which is less than 1/40 of the contents of ADH1 
or 3 in the liver [20,59]. Moreover, the contribution of the stomach to first pass metabolism (FPM) is 
known  to  be  much  smaller  than  the  liver  [55].  Therefore,  the  involvement  of  ADH4  in  alcohol 
metabolism may be small even in FPM.  
13. Physiological Roles of ADH3 and Alcohol-Related Diseases 
It  goes  without  saying  that  ADHs  essentially  exist  in  human  body  to  carry  out  physiological 
metabolisms, aside from their ability to metabolize the alcohol that a person imbibes. In fact, they play 
important  roles  in  the  metabolism  of  physiological  alcohol  and  aldehyde  derivatives,  such  as 
neurotransmitters  with  active  amines  (dopamine  [60],  norepinephrine  [61],  serotonin  [62]  etc.), 
cholesterols [63], steroids [64,65], bile acids [66], and Vitamin A [67]. ADH 3, in particular, is found 
in all living organisms as the ancestor of other forms of ADH, and is considered to play an important 
role  in  basic  cell  metabolism  [68].  For  example,  ADH3  is  identical  to  glutathione-dependent 
formaldehyde dehydrogenase (GSH/FADH) [69], which is  the enzyme  responsible for detoxifying 
formaldehyde  in  the  body  [26].  In  addition,  the  s-nitrosoglutathion  (GSNO)  reductase  activity  of 
ADH3 plays a key role in NO metabolism [70]. ADH3 may also be involved in anti-inflammatory, 
anti-allergic reactions and blood pressure by metabolizing 20-OH leukotriene B4 [71] and other ω-OH 
fatty  acids  [72].  Moreover,  all  ADH  isozymes  oxidize  retinol  (Vitamin  A),  and  ethanol  strongly 
inhibits this activity [73]. Deltour et al. considered the inhibition of retinoic acid synthesis by ethanol 
to be a potential mechanism for fetal alcohol syndrome (FAS) [74]. Retinoic acid, the metabolite of 
Vitamin A, plays an important role in the neural development of vertebrates [75]. Molotkov et al. have 
demonstrated that ADH3 is a key enzyme in the systemic metabolism of Vitamin A, although it shows 
little activity for Vitamin A in vitro [67]. It also regulates the content of retinoic acid in the brain, 
because it is the sole ADH in the brain [23,42]. So, it seems that FAS, which is accompanied by 
various  neuronal  abnormalities,  arises  because  ethanol  inhibits  retinol  metabolism  through  ADH3 
inhibition in an embryo or a fetus brain. Thus, ADH3 is a multifunctional house-keeping enzyme with Int. J. Environ. Res. Public Health 2010, 7                 
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a wide specificity for substrates and is responsible for various metabolic functions essential for life, 
including  the  detoxification  of  cytotoxins.  So,  it  is  easy  to  imagine  that,  in  heavy  drinkers,  the 
continuous drinking of alcohol disturbs the basic metabolism and causes the collapse of homeostasis 
by inhibiting the many functions of ADH3. The idea that alcohol-related disorders are induced when 
ethanol inhibits physiological metabolism through the mechanism of ADHs is as important as ideas on 
the toxicity of ethanol and its metabolites themselves. 
14. Conclusion 
This review described a new view of ADH 3 in the fields of alcohol metabolism and the bioaction 
of ethanol, and compared the new face of ADH3 to the well-known ADH1. ADH 3 contributes to 
alcohol  metabolism  during  acute  alcohol  intoxication  and  diminishes  the  symptoms,  thereby 
supporting  ADH1.  Solution  hydrophobicity  increases  ADH3  activity  at  the  kinetic  level,  and  cell 
damage accompanied by hydrophobicity does so at the enzyme content level. A dose of alcohol large 
enough to damage the liver increases the ADH3/ADH1 activity ratio and lowers the rate of alcohol 
metabolism, which in turn nonlinearly increases the AUC. The interdependent increase in AUC and 
the ADH3/ADH1 activity ratio may be a factor in the development of liver disease. In alcoholics with 
liver disease, ADH3 activity increases with total alcohol intake, while ADH1 activity decreases. This 
suggests that ADH3 plays an important role in the alcohol metabolism of alcoholics with severe liver 
disease, compensating for the reduced role of ADH1. This adaptive role of ADH3 after chronic binge 
drinking makes it possible for alcoholics to drink themselves to death in spite that the rate of alcohol 
metabolism  is  lowered.  Thus,  it  may  be  important  to  regulate  ADH3  activity  to  prevent  the 
development of alcoholism. 
Our theory about alcohol metabolism and alcoholism is still at the research level. We welcome a 
thorough examination of it through experiments and discussions in various fields. 
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*   The  term  ―non-ADH  pathway‖  was  invented  when  only  one  mammalian  ADH  isozyme  was 
known  to  exist,  namely,  Class  I  ADH  (ADH1).  Today,  we  know  of  six  mammalian  ADH 
isozymes; classified as Class I to VI in order of discovery [76]. Class I, II, III, and IV ADHs are 
present in every mammal and are called ADH 1, 2, 3 and 4, respectively. Accordingly, the term 
―non-ADH  pathway‖  actually  means  the  non-ADH1  pathway.  In  humans,  ADH1  is  further 
classified  into  three  subcategories:  ADH1A  (formerly  ADH1),  1B  (formerly  ADH2)  and  1C 
(formerly ADH3), which contain a homodimer of subunit ʱ, β, and γ, respectively. The amino acid Int. J. Environ. Res. Public Health 2010, 7                 
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sequences for the three ADH1 isozymes are about 91% homologous [77]. On the other hand, 
ADH2 (formerly ADH4), 3 (formerly ADH5), and 4 (formerly ADH7) contain a homodimer of 
subunit π, χ, and ʴ (μ), respectively. The amino acid sequences of ADH 1, 2, 3, and 4 are about 
60% homologous [77]. The Km for ethanol increases in the order ADH 1, 2, 4, 3, with the values 
being around 1 mM, several tens of millimoles, several hundred millimoles, and several moles, 
respectively [13,16]. The insensitivity to pyrazoles, which are specific inhibitors of ADH, also 
increases in the same order [13,16]. Thus, among mammalian ADH isozymes, ADH3 has the 
highest Km for ethanol and the lowest sensitivity to pyrazoles, while ADH1 has the lowest Km and 
the  highest  sensitivity.  Unlike  other  ADHs,  which  have  limited  tissue distributions,  ADH3  is 
present in almost all mammalian tissues. Moreover, ADH3 exists in all biological kingdoms, while 
other mammalian ADHs appear first in vertebrates. So, ADH3 is considered to be the ancestor of 
all other ADHs [68]. 
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